Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours

被引:9
作者
Ahmad, Firoz [1 ]
Surve, Purva [1 ]
Natarajan, Sripriya [1 ]
Patil, Ashwini [1 ]
Pol, Smita [2 ]
Patole, Kamlakar [2 ]
Das, Bibhu Ranjan [1 ]
机构
[1] SRL Ltd, Res & Dev Div, Plot 1,Prime Sq Bldg,SV Rd, Mumbai, Maharashtra, India
[2] SRL Ltd, Histopathol Div, Plot 1,Prime Sq Bldg,SV Rd, Mumbai, Maharashtra, India
关键词
RASSF1A MGMT gene methylation; KRAS mutation; Testicular Germ cell tumors; India; C-KIT; ACTIVATING MUTATIONS; METHYLATION PROFILES; PROMOTER METHYLATION; SOMATIC MUTATIONS; RAS MUTATIONS; K-RAS; ASSOCIATION; SEMINOMA; CANCER;
D O I
10.1016/j.cancergen.2019.10.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Testicular germ cell tumor (TGCT) development may involve a series of modification at epigenetic and genetic level which may act synergistically and transform the primordial gonocyte. This study evaluated the frequency and distribution pattern of RASSF1A/MGMT gene methylation and KRAS, BRAF and cKIT gene mutation in Indian TGCT patient, and their correlation with clinicopathological features. Forty-one TGCT tumors were used to investigate hypermethylation of RASSF1A and MGMT gene and mutations of KRAS codon 12/13, BRAF V600E and cKIT exon 17 mutations. RASSF1A and MGMT methylation was noted in 58.5% and 10% of the TGCTs. A higher frequency of RASSF1A methylation was noted in seminomas (71%, 17/24), while MGMT methylation was frequent in mixed tumors (23%, 3/13). Interestingly, 3 of 41 cases showed concurrent methylation of both the genes. The absence of tumor necrosis was significantly associated with increased frequency of MGMT hypermethylation (30% vs. 3%, p = 0.03). KRAS mutation was identified in 17% (7/41), while none showed BRAF and cKIT mutation. KRAS mutations were predominantly found in codon 12 with G12V as the most recurrent mutations. Mixed germ tumors tends to show increased frequency of KRAS mutation (31%, 4/13), followed by pure seminomas (4%, 1/24). Interestingly, KRAS mutation rate was significantly higher in metastatic tumors in comparison to primary tumors (100% vs. 13%, p = 0.02). No other association of RASSF1A/MGMT/KRAS alterations with other clinicopathological features was noted. In conclusion, these data support the notion that the cancer-associated alterations in the RASSF1, MGMT and KRAS gene may significantly contribute to TGCT pathogenesis. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:42 / 50
页数:9
相关论文
共 38 条
  • [1] Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours
    Agathanggelou, A
    Honorio, S
    Macartney, DP
    Martinez, A
    Dallol, A
    Radar, J
    Fullwood, P
    Chauhan, A
    Walker, R
    Shaw, JA
    Hosoe, S
    Lerman, MI
    Minna, JD
    Maher, ER
    Latif, F
    [J]. ONCOGENE, 2001, 20 (12) : 1509 - 1518
  • [2] Molecular evaluation of BRAF V600 mutation and its association with clinicopathological characteristics: First findings from Indian malignant melanoma patients
    Ahmad, Firoz
    Avabhrath, Nagashree
    Natarajan, Sripriya
    Parikh, Jeenal
    Patole, Kamlakar
    Das, Bibhu Ranjan
    [J]. CANCER GENETICS, 2019, 231 : 46 - 53
  • [3] Molecular evaluation of BRAF gene mutation in thyroid tumors: Significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of aggressive disease
    Ahmad, Firoz
    Nathani, Richa
    Venkat, Janani
    Bharda, Anahita
    Vanere, Veena
    Bhatia, Simi
    Das, Bibhu Ranjan
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2018, 105 (03) : 380 - 386
  • [4] The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
    Bamford, S
    Dawson, E
    Forbes, S
    Clements, J
    Pettett, R
    Dogan, A
    Flanagan, A
    Teague, J
    Futreal, PA
    Stratton, MR
    Wooster, R
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (02) : 355 - 358
  • [5] Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients
    Bhaumik, Sangeet
    Ahmad, Firoz
    Das, Bibhu Ranjan
    [J]. MEDICAL ONCOLOGY, 2016, 33 (10)
  • [6] c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma
    Biermann, K.
    Goeke, F.
    Nettersheim, D.
    Eckert, D.
    Zhou, H.
    Kahl, P.
    Gashaw, I.
    Schorle, H.
    Buettner, R.
    [J]. JOURNAL OF PATHOLOGY, 2007, 213 (03) : 311 - 318
  • [7] Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma
    Bisht, Swati
    Ahmad, Firoz
    Sawaimoon, Satyakam
    Bhatia, Simi
    Das, Bibhu Ranjan
    [J]. MEDICAL ONCOLOGY, 2014, 31 (09) : 1 - 13
  • [8] Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors
    Boublikova, L.
    Bakardjieva-Mihaylova, V.
    Kramarzova, K. Skvarova
    Kuzilkova, D.
    Dobiasova, A.
    Fiser, K.
    Stuchly, J.
    Kotrova, M.
    Buchler, T.
    Dusek, P.
    Grega, M.
    Rosova, B.
    Vernerova, Z.
    Klezl, P.
    Pesl, M.
    Zachoval, R.
    Krolupper, M.
    Kubecova, M.
    Stahalova, V.
    Abrahamova, J.
    Babjuk, M.
    Kodet, R.
    Trka, J.
    [J]. CANCER LETTERS, 2016, 376 (02) : 367 - 376
  • [9] DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma
    Brait, M.
    Maldonado, L.
    Begum, S.
    Loyo, M.
    Wehle, D.
    Tavora, F. F.
    Looijenga, L. H. J.
    Kowalski, J.
    Zhang, Z.
    Rosenbaum, E.
    Halachmi, S.
    Netto, G. J.
    Hoque, M. O.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (02) : 414 - 423
  • [10] Interpreting the international trends in testicular seminoma and nonseminoma incidence
    Bray, Freddie
    Ferlay, Jacques
    Devesa, Susan S.
    McGlynn, Katherine A.
    Moller, Henrik
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (10): : 532 - 543